Trius plans to list on the NASDAQ under the symbol TSRX. The San Diego biotech passed a key Phase ...
TSRX) for an aggregate upfront cash consideration of approximately $704 million. Effective today, Trius common stock will cease to be traded on the NASDAQ. “We are very pleased to complete this acquisition and …
Business Wire
This is a field where new products and clinical advances significantly boost the price of a company’s stock – and can attract buyouts. Take the case of Trius Therapeutics (Nasdaq: TSRX), which I mentioned to you on March …
Big
Exciting Biotech Stocks Investing Ideas Have Explosive Potential :: The Market Oracle :: The Market Oracle Home Free Newsletter RSS Feed Help FAQ Terms of Use Privacy Policy Submit Articles Advertising About …
The stock went down with the approval announcement ... TLSR: Steve, you and I spoke about Trius Therapeutics Inc. (TSRX:NASDAQ) the last time we talked. We’re coming up, I believe, on a second phase 3 pivotal trial …
Having said that, sure should be sweet for CellDex (CLDX) — a stock I bought in the $11 range and highlighted ... Sarepta Theraputics (SRPT), Acadia Pharma (ACAD), Trius Theraputics (TSRX), NPS Pharma (NPSP). FYI, …
12. Painting and packaging finished appliances. T. Trading securities ___ 1. 35% of the nonvoting preferred stock of American Aircraft Company. M. Securities held-to-maturity ___ 2. Treasury bills to be held to maturity. A. …
That means the VC-backed IPO pipeline remains static with 42 registrants ... It plans to trade on the Nasdaq under ticker symbol TSRX, with Credit Suisse serving as lead underwriter. The company recently set its IPO …
If you own shares of Trius common stock and wish to discuss the legal ramifications of ... by visiting http://brodsky-smith.com/624-tsrx-trius-therapeutics-inc.html, or calling toll free 877-LEGAL-90. Brodsky & …